Should Off-Label Comparators Be Used In HTAs? Swedish Court Investigates
This article was originally published in Scrip
Should an off-label use of an existing medicine be allowed as a comparator when conducting health technology assessments on new drugs? Some prominent European HTA bodies, like the National Institute for Health and Care Excellence (NICE), are quite happy to include off-label uses in their evaluations, but others, including many in the originator industry, feel such comparisons are not necessarily valid.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.